News & Updates
Showing Multidisciplinary articles
Showing
GLP-1 RA benefit may branch out into obesity-related cancers
Another feather may have been added in the cap of glucagon-like protein-1 receptor agonists (GLP-1 RAs) – the class of type 2 diabetes (T2D) drugs that has become a blockbuster recently due to their remarkable weight loss benefit – as evidence of their potential to reduce the risk of obesity-associated cancers (OACs) comes to light.
COVID-19 variants carry no increased autoimmune sequelae risk
COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.
Cruciferous vegetables help avert recurrence in NMIBC patients on BCG
Higher consumption of raw cruciferous vegetables appears to reduce the risk of recurrence in nonmuscle-invasive bladder cancer (NMIBC) patients treated with induction bacillus Calmette-Guérin (BCG), suggests a study.
Canagliflozin lowers HbA1c in children with T2D
Treatment with canagliflozin results in clinically meaningful reductions in glycated haemoglobin (HbA1c), when compared with placebo, in children and adolescents with type 2 diabetes (T2D), as shown by the results of a phase III study presented at EASD 2024.
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
Adding sodium–glucose co-transporter-2 (SGLT2) inhibitors to usual care in the treatment of hospitalized patients with COVID-19 does not necessarily lead to improved survival, according to the results of a meta-analysis.